Aims: There is no quantitative data on the mRNA expression of epidermal growth factor receptor (EGFR) and transformation growth factor alpha (TGF-α) in thyroid carcinoma. The aims of this study are to detect, quantify and analyse the clinicopathological correlations of the expression of these genes in a large cohort of patients with thyroid carcinoma. 
INTRODUCTION
Transforming growth factor alpha (TGF-α) is a 50-amino acid single chain polypeptide of 5.6 kDa [1] . This small polypeptide shares around 30% structural similarity with epidermal growth factor (EGF) but distinctly competes for the common receptor, epidermal growth factor receptor (EGFR) [2] . TGF-α is the most potent angiogenic factor among the ligands that bind to EGFR as well as a strong collaborator in promoting carcinogenesis by other oncogenes [3] . Over-expression of TGF-α has been found in various types of human cancers [4] [5] [6] [7] . Moreover, TGF-α has been proved to stimulate invasion and growth of thyroid cancer cells in culture [8] . Taken together, TGF-α is highly related to carcinogenesis and aggressiveness.
EGFR is a transmembrane glycoprotein which consists of 1186 amino acids.
Once ligands bind to EGFR, this kinase triggers different downstream signalling pathways and results in biological responses varying from proliferation, differentiation, migration and apoptosis [9] . EGFR is one of the receptors often found up-regulated in human carcinomas and often related to poor prognosis or advanced pathological stages [10] [11] .
Thyroid cancer is the most common endocrine malignancy and approximately 75% of patients with thyroid cancer have papillary thyroid carcinoma (PTC) [12] . In papillary thyroid carcinoma, RET/PTC re-arrangement is a common genetic event [13] . Recent study suggests that RET/PTC-induced cell growth is mediated in part by EGFR [14] . Also, PTC stromal invasion may be regulated through EGFR-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A [15] .
Gene therapy is believed to be important in the management of cancer [16] .
EGFR-targeted therapy has emerged as a promising therapeutic approach in some cancer patients [17] . In thyroid cancer, mutational events and gene amplification may identify a minor portion of thyroid cancers that may benefit from EGFR inhibitors [18] [19] . Also, it is likely that identification of the presence and level of TGF-α and EGFR expression is useful when using the gene therapy in human cancers.
To the best of our knowledge, there is no study to quantify the levels of mRNA expression of TGF-α and EGFR in papillary thyroid carcinoma. Also, there is no study comparing these genes' expressions in the cancer tissue and adjacent non-cancer thyroid tissue. In this study, we quantified the TGF-α and EGFR mRNA expression level in thyroid carcinomas and compared that with adjacent non-cancer thyroid carcinomas. The expression of these mRNA was also correlated with their protein expressions and the clinicopathological features in a large cohort of patients.
MATERIALS AND METHODS

Patients and tissue samples
Seventy-one patients (17 men, 54 women) with PTC who had a median age of 46.5 years (12-85 years) were recruited in this study. Informed consent was obtained from all patients to collect their tissues samples for conducting this study. The mean size of the tumours was 2.5 cm (1-9cm). For controls, 20 patients (5 men, 15 women) with benign thyroid disease (nodular goitre) were used. The PTCs were staged according to TNM (tumour, lymph node, metastases) and MACIS (metastases, age, completeness of resection, invasion, size) staging systems [20] [21] . The TNM was used as it is the most commonly used staging system [20] . According to the TNM staging system, 31 were stage I, 7 were stage II, 32 were stage III and 1 was stage IV cancers. MACIS by Mayo Clinic was also adopted as it is the most predicting staging system in thyroid cancer [21] . Most patients fall into the low risk category (MAICS score <6) and are cured of the cancer at the time of surgery. On MACIS system, the cancers were divided into 4 risk groups. There were 42 group 1 (score <6) cancers, 9 group 2 (6-6.99) cancers, 13 group 3 (7-7.99) cancers and 7 group 4 (>8) cancers.
Management was by a pre-agreed standardized multidisciplinary protocol. The follow-up period was defined as the interval between the date of surgery for thyroid carcinoma and the date of death or closing date of the study. The actual survival rate of the patients was calculated from the date of surgical resection of the thyroid cancers to the date of death or last follow-up. Only cancer-related death was counted as end point in the statistical analysis. The disease-free survival was calculated from the time of surgery to the date of first recurrence of the cancer. The mean follow up of the patients was 40 months (range 2 to 94 months). In the follow-up period, 11 patients had recurrent disease and with 2 died of PTC.
Tissue samples were obtained directly after surgery. For PTC, samples were taken both from the cancer and the non-cancer area in the contra-lateral lobe of thyroid. A part of the samples was snap-frozen in liquid nitrogen immediately and stored at -80 o C for RNA extraction. The rest was fixed in 10% buffered formalin for paraffin embedding. These paraffin blocks were used in immunohistochemistry and haematoxylin and eosin (H&E) staining. H&E staining was used to confirm the pathological diagnosis by the author who is a pathologist (AKYL.) before starting this research. Eighty per cent (57 of 71) of PTC were conventional and 13% (9 of 71) were papillary micro-carcinomas. The other histological variants were 4% (n=3) follicular variant and 3% (n=2) tall cell variant. Also, the clinical and pathological parameters of the thyroid cancers were reviewed and entered into database for analysis. In addition, 20 tissues samples obtained from patients with nodular goitre were used as non-cancer controls.
RNA extraction and reverse transcription
Total RNA was extracted from frozen thyroid tissues using TriZol reagent Afterwards, the slides were briefly counterstained with haematoxylin, mounted in crystal mount, and cover-slipped in 50:50 xylen-Permount.
The immunochemical staining for TGF-α and EGFR were examined and scored by the author (AKYL) blinded to the qPCR results of the specimens. In both reactions, the staining was mainly in the cytoplasm. Thus, brown cytoplasmic staining was labelled as positive. The results of immunochemical staining were assessed semi-quantitatively divided into three categories: 0 to 30% positive (1+); 31
to 60% positive (2+) and 61 to 100% (3+).
Statistical analysis
All the clinical, pathological, follow-up, mRNA expression and protein expression data were computerized. Statistical analysis was performed using the 
RESULTS
mRNA expression of TGF-α and EGFR in different thyroid tissues
The mRNA expression of TGF-α and EGFR was compared in 71 PTC, 68 adjacent non-caner thyroid (in contra-lateral lobe) and 20 benign thyroid tissues.
Significant difference in the mRNA expression level was found for TGF-α and EGFR in PTC against adjacent non-cancer thyroid (in contra-lateral lobe) and benign thyroid tissues (p <0.0001 and p < 0.05 respectively) (Figure 1 ).
High level of expression of TGF-α mRNA was noted in 77% (55 of 71) of PTCs.
The other PTCs showed either TGF-α mRNA in normal range (10%; n=7) or reduced level (13%; n=9). Also, high level of expression of EGFR mRNA was noted in 54%
(38 of 71) of PTCs. The other PTCs showed either EGFR mRNA in normal range (6%; n=4) or reduced level (40%; n=29).
The correlations between the expression levels of TGF-α and EGFR mRNA in PTC and the adjacent morphologically non-cancer tissue were studied in 68 cases in which the adjacent non-cancer tissues were available (Table 2 ). In 25% ( 
Immunochemical detection of TGF-α and EGFR in thyroid tissues (Figure 2)
All of 59 PTC were stained positively by TGF-α and EGFR antibodies whereas only 30% of benign thyroid tissues were positive. The adjacent non-cancer tissues were either negative or showed only 1+ staining for both antibodies. For TGF-α protein expression in PTC, 10 % (n=6) has 1+ staining, 7% (n=4) had 2+ staining and 83% (n=49) had 3+ staining. For EGFR protein expression in PTC, 10 % (n=5) has 1+ staining, 7% (n=6) had 2+ staining and 83% (n=48) had 3+ staining.
Correlations between the expression of mRNA and proteins of TGF-α and EGFR
PTCs with 1+ expression of TGF-α protein had a mean fold change of TGF-α of 3.8 while those with either 2+ or 3+ TGF-α had a mean fold change of 15.9 (p=0.0001). Also, 89% (42 of 46) of patients with high level of expression of TGF-α mRNA showed either 2+ or 3+ TGF-α protein expression.
The fold change in EGFR mRNA was correlated with EGFR expression. In
PTCs with 1+ expression of EGFR protein, the mean fold change was 2.2 while those with 2+ or 3+ expression of EGFR protein, the mean fold change was 7.25 (p=0.029).
In addition, 93% (28 of 30) of patients with high level of expression of EGFR mRNA also showed either 2+ or 3+ EGFR protein expression.
The relationship between TGF-α and EGFR mRNA expression in PTC
The correlation between mRNA expression of TGF-α and EGFR in PTC was examined by Pearson correlation test. Positive correlation between these genes was observed (p<0.0001) ( Figure. 3). Over-expression of both TGF-α and EGFR mRNA was noted in 52% (37 of 71) and normal or under-expression of both TGF-α and EGFR mRNA was observed in 21% (15 of 71) of the PTCs. Thus, 73% of patients with PTC had similar trend in expression of these mRNA.
The positive correlation between TGF-α and EGFR expression was also noted at the protein level (p=0.0001). High level of expression (3+) of both TGF-α and EGFR proteins were found in 75 % (44 of 59) whereas low level of expression (1+) of both proteins was noted in 8% (5 of 59) of patients with PTC. Overall, 83% of patients with PTC had a similar trend in expression of these proteins. (Table 3) The mean TGF-α fold change of PTCs showing lymphovascular permeation was 26 whereas mean fold change of PTCs without lymphovascular permeation was 12 (p=0.02). Other than this, the TGF-α mRNA expression did not correlate with other clinical and pathological parameters of the PTCs. 
Association of TGF-α and EGFR mRNA in PTC with clinicopathological parameters
The clinical and pathological relevance of TGF-α and EGFR proteins expression (Table 4)
In the patients with multi-focal PTC in the thyroid, 71% (20 of 28) had 3+ TGF-α protein expression whereas in the patients with solitary PTC in thyroid, 94% 
The prognosis of patients with PTC in relationship with TGF-α and EGFR expression
The mean fold change of EGFR mRNA for patients with recurrent disease was 2 while that of other patients was 8. Thus, the difference in level of EGFR mRNA expression was significant between the 2 groups (p=0.002). Other than this, the survival or disease free survival rates of the patients with PTC were not related to the levels of protein or mRNA expression of either TGF-α or EGFR.
DISCUSSION
Up-regulation of EGFR or TGF-α has been found in papillary thyroid carcinoma [23] [24] [25] [26] [27] [28] [29] [30] . In addition, co-expression of these genes in thyroid carcinomas was also noted [23, 24] . All these studies demonstrated the increased expression of EGFR or TGF-α in thyroid carcinoma through immunohistochemistry and slot-blot approach.
However, these qualitative methods are hard to achieve statistical analysis.
Furthermore, studies on TGF-α expression in thyroid carcinoma were based on small number of cases [23, 24, 28, 29] . To the best of our knowledge, the current study In this study, we noted that a high portion of morphological non-cancer tissue adjacent to the thyroid cancer showed high expression of mRNA for both TGF-α and EGFR. It is worth noting that we have reported higher expression of VEGF protein in non-cancer thyroid tissue [31] . The findings can be explained by the presence of genetic changes in the tissue before the morphological appearance of cancer or by the presence of intra-glandular spread of micro-metastases not detected by morphological examination. Thus, non-cancer thyroid tissue from cancer patient harbour genetic changes and cannot be used as negative control in the study of genetic changes in cancer.
Up-regulation of TGF-α mRNA was noted in PTC when compared with either benign thyroid lesions or paired non-cancer thyroid tissue adjacent to the PTC. Also, the higher levels of TGF-α mRNA in PTC correlated with higher levels of protein expression as detected by immunohistochemistry. Seventy-seven per cent of PTC had high level of TGF-α mRNA expression and 90% had 2+/3+ level of protein expression. Thus, TGF-α was confirmed to be increased in both mRNA and protein level in PTC.
We noted that higher level of TGF-α expression was associated with more frequent lympho-vascular permeation. On the other hand, higher level of protein expression of TGF-α expression was related to lower prevalence of macroscopically multi-focal cancer in the thyroid. Thus, the presence of macroscopically multi-focality of the thyroid cancer may be related to mechanisms other than lympho-vascular permeation. Overall, though TGF-α expression is not a prognostic parameter, it may play a role in micro-invasiveness in PTC.
EGFR mRNA and protein expression was more often noted in PTCs than benign thyroid lesions. High level of expression of EGFR mRNA and protein was noted in 54% and 90% of PTCs. It is worth noting that higher level of EGFR protein expression was more important in early stage thyroid cancer. It is likely that EGFR expression was related to early phase of carcinoma progression. Also, EGRF expression has been shown to be independent factor for predicting cancer recurrences in PTC [25, 27] . In this study, we noted that the level of EGFR mRNA expression predicted thyroid cancers with recurrence. However, the level of expression was not related to the survival rate of patients with PTC. The results should be confirmed in a larger series with longer follow-up period.
EGFR protein expression can occur both in the cytoplasm and the membrane of the cells [32] . The switch from greater cytoplasmic EGFR to greater membranous EGFR expression occurs in progression in some cancers [33] . In this study, the staining EGFR in thyroid carcinoma was mainly cytoplasmic. This may in concur with the suggestion that EGFR protein expression is an early event in thyroid cancer. Different variants of PTC had different clinical and pathological features [12] . In the current study, we noted that the level of expression of EGFR mRNA was different in conventional PTC, papillary micro-carcinoma, follicular variant of PTC and tall cell variant. It seems that higher expression of EGFR mRNA was noted in PTC variant with less biological aggressive variants. It is worth noting that genetic 20 differences have been observed in different variants of PTC [34] [35] [36] . However, more cases of histological variants of PTC may need to be studied to confirm the difference in EGFR mRNA expression in different histological variants of PTC.
To conclude, this is the first documented report demonstrating the increased levels of TGF-α and EGFR mRNA in thyroid carcinoma through a quantitative approach. The mRNA expression of these genes was also correlated with the protein expression. Up-regulated TGF-α and EGFR may be related to the pathological parameters of thyroid carcinoma. The finding of high level of expression of these genes in many PTCs may provide useful information when considering gene targeting therapies for this cancer. --------------------------------------------------------------------------------------------------- 
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